Unravelling the Triple Helix: Collagenase as a Versatile Industrial Biocatalyst

Unravelling the Triple Helix: Collagenase as a Versatile Industrial Biocatalyst

Collagen's tightly wound triple-helical conformation endows it with exceptional mechanical resilience, placing it among nature's most recalcitrant proteins; remarkably, collagenase is the sole enzyme capable of cleaving this robust architecture efficiently under physiological conditions.Collagen's tightly wound triple-helical conformation endows it with exceptional mechanical resilience, placing it among nature's most recalcitrant proteins; remarkably, collagenase is the sole enzyme capable of cleaving this robust architecture efficiently under physiological conditions.

Microbial collagenases fall into two structural families: the matrix metalloproteinase (MMP) family, which includes vertebrate collagenases, and the U32 peptidase family, to which many bacterial collagenases belong. The Bacillus siamensis Z1 collagenase is classified within the U32 family, it employs a distinct active-site architecture to unwind and cleave the collagen triple helix. Mechanistically, bacterial collagenases bind to native triple-helical collagen and introduce endopeptidic cleavages at glycine-rich sites within the repeating Gly-X-Y units, disrupting the stable helical conformation and generating shorter fragments susceptible to further proteolysis. The recombinant Z1 collagenase has demonstrated robust activity against both collagen and gelatin, and molecular docking studies revealed a binding affinity of −12.7 kcal/mol for marine collagen peptides.

Collagen’s tightly packed triple-helical structure gives it remarkable mechanical strength and makes it one of the most resistant proteins to degradation. Collagenase is particularly important because it is capable of efficiently breaking down this stable structure under physiological conditions. In the cosmetics industry, collagenase is used in anti-ageing formulations, while the resulting collagen-derived peptides are widely utilized in skincare products. More recently, Revankar and Bagewadi (2026) reported an innovative application in which collagenase-generated hydrolysates served as both reducing and capping agents in the green synthesis of silver and zinc oxide nanoparticles. The resulting nanoparticles demonstrated antibacterial activity as well as cytotoxic effects against breast cancer cell lines.

Collagenases are produced by diverse microorganisms. Clostridium histolyticum has historically been the dominant commercial source, while marine vibrios such as Vibrio alginolyticus and actinomycetes including Streptomyces violaceoruber are also potent producers. The recently characterised Bacillus siamensis strain Z1, isolated from marine water along the coast of Goa, India, achieved optimised collagenase production of 4.55 U/mL and efficiently degrades collagen, making it a promising industrial candidate. Other recent additions include Bacillus velezensis LZ676, reported to completely hydrolyse cowhide collagen with significant antioxidant activity.

The marine environment plays a significant role in shaping the properties of the Z1 enzyme. Coastal areas surrounding fish-processing facilities often accumulate large quantities of collagen-rich waste, providing a selective environment for microorganisms capable of degrading collagen. As a result, marine-derived collagenases have developed several adaptive characteristics. These include optimal activity under alkaline conditions, with the recombinant Z1 enzyme showing peak activity at pH 9.0, consistent with the slightly alkaline nature of seawater. The enzyme also exhibits moderate thermostability, with an optimum temperature of approximately 50 °C, which enhances its potential for industrial applications. In addition, its natural halotolerance allows it to remain active at relatively high salt concentrations. The enzyme also demonstrates a preference for marine collagen substrates, which differ from mammalian collagen in their amino acid composition and degree of cross-linking.

Rigorous toxicity testing is mandatory before deploying microbial enzymes in food or pharmaceutical contexts. The European Food Safety Authority (2024) evaluated food enzyme microbial collagenase from a genetically modified Streptomyces violaceoruber strain: the Ames test and in vitro chromosomal aberration assay both raised no safety concerns. A 90-day oral toxicity study in rats established the no observed adverse effect level at 234.9 mg total organic solids per kg body weight per day, the highest dose tested. Material safety data sheets classify C. histolyticum collagenase as a potential skin and eye irritant but not as a systemic toxicant or carcinogen. Since industrial enzymes are typically processing aids rather than final-product ingredients, consumer exposure is negligible, and EFSA concluded that the enzyme raises no safety concerns under intended use.

Collagenase production from B. siamensis Z1 proceeds via submerged fermentation, the dominant industrial method for bacterial enzymes. Revankar and Bagewadi (2026) systematically optimised parameters — inoculum size, carbon source (glucose), nitrogen source (yeast extract), Ca²⁺ supplementation, pH 8.0, and 37 °C — achieving a remarkable 17.93-fold yield enhancement through response surface methodology. Submerged fermentation is preferred because it allows real-time control of dissolved oxygen, pH, and nutrients; supports straightforward scalability; and facilitates downstream processing since the extracellular enzyme is directly available in the broth. Semi-solid fermentation has been explored for fungi such as Aspergillus serratalhadensis using agro-industrial substrates, but remains less common for bacterial production due to Bacillus species' preference for liquid culture and the greater difficulty of controlling process parameters in solid matrices.

Enzyme immobilisation enhances reusability, operational stability, and ease of separation. For collagenase, several approaches have been studied: entrapment within alginate–chitosan composite beads, which reduces leaching and improves mechanical robustness; covalent binding onto glutaraldehyde-activated silica or epoxy resins, which virtually eliminates leaching; adsorption onto hydroxyapatite or magnetic nanoparticles, enabling magnetic recovery from reaction mixtures — especially attractive for biomedical applications; and cross-linked enzyme aggregates, forming insoluble, support-free catalytic bodies with high volumetric activity. Across methods, immobilisation typically shifts the temperature optimum upward, broadens pH tolerance, extends operational half-life, and enables reuse across five to ten or more batch cycles, significantly reducing per-unit enzyme cost.

The industrial-scale bioreactor for collagenase production is the stirred-tank reactor. As a strictly aerobic organism, B. siamensis requires continuous oxygen supply, and the impeller system ensures homogeneous distribution of dissolved oxygen, nutrients, and cells. The reactor operates with feedback control of pH, temperature, dissolved oxygen, and foam level — all parameters shown to profoundly influence yield. Fed-batch operation is particularly advantageous: controlled incremental nutrient addition avoids substrate inhibition, enabling higher cell densities and sustained production. Stirred-tank reactors scale from laboratory volumes up to 50,000 litres using well-established scale-up principles, confirming them as the industry standard for aerobic bacterial fermentations.

The global collagenase market was valued at approximately USD 450 million in 2024 and is projected to reach USD 785 million by 2033, growing at a compound annual growth rate of 7.2 per cent. Demand is fuelled by expanding pharmaceutical use (Xiaflex® alone generating over USD 600 million in peak annual revenue), surging collagen peptide popularity in functional foods and nutraceuticals, the fish processing industry's need to valorise waste, and the leather industry's shift toward enzymatic alternatives.

The economic viability of large-scale collagenase production hinges on a vertically integrated, waste-to-value business model. Raw material costs — typically 30 to 40 per cent of total expenditure — are dramatically reduced by substituting synthetic media with agro-industrial and fishery by-products such as fish skin collagen waste, soybean meal, and molasses. Fermentation proceeds in high-volume fed-batch stirred-tank reactors, with parameters optimised via statistical design. Downstream processing is streamlined by exploiting the enzyme's extracellular nature: ultrafiltration replaces chromatography for industrial-grade product, with affinity purification reserved for pharmaceutical-grade batches commanding premium pricing. Immobilisation on reusable supports reduces per-unit enzyme cost by 40 to 60 per cent. A tiered pricing strategy — high-purity collagenase at USD 500–5,000 per gram for pharmaceuticals, bulk enzyme at USD 50–200 per kilogram for food and leather — captures maximum value. Co-production of bioactive collagen peptides (USD 10–50 per kilogram as nutraceuticals) alongside the enzyme creates a dual-revenue stream, and locating facilities near coastal fishery hubs minimises logistics costs while tapping waste valorisation subsidies, completing a model that is both environmentally sustainable and economically competitive.

In conclusion, collagenase stands as a paradigm of how a single enzyme, sourced from the natural microbial world, can catalyse transformations across an extraordinary breadth of industrial sectors. Its unique ability to degrade the recalcitrant triple helix of collagen has unlocked value in medicine, food, leather, cosmetics, and nanotechnology. With powerful new microbial producers such as Bacillus siamensis strain Z1, advances in fermentation optimisation, enzyme immobilisation, and safety validation, collagenase is poised to meet the demands of a global market projected to nearly double in value over the coming decade. The convergence of waste-to-value economics, sustainability imperatives, and biotechnological innovation ensures that this remarkable enzyme will remain at the forefront of industrial biotechnology for years to come.